Effects of a nanocomposite containing Orbignya speciosa lipophilic extract on Benign Prostatic Hyperplasia.

[1]  J. Morote,et al.  Antiproliferative and apoptotic effects of the herbal agent Pygeum africanum on cultured prostate stromal cells from patients with benign prostatic hyperplasia (BPH) , 2010, The Prostate.

[2]  S. Yamada,et al.  Pharmacologically relevant receptor binding characteristics and 5alpha-reductase inhibitory activity of free Fatty acids contained in saw palmetto extract. , 2009, Biological & pharmaceutical bulletin.

[3]  D. Rowley,et al.  Keratinocyte‐derived chemokine induces prostate epithelial hyperplasia and reactive stroma in a novel transgenic mouse model , 2009, The Prostate.

[4]  J. Gustafsson,et al.  A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia , 2009, Proceedings of the National Academy of Sciences.

[5]  P. Zancan,et al.  Crude ethanol extract from babassu (Orbignya speciosa): cytotoxicity on tumoral and non-tumoral cell lines. , 2008, Anais da Academia Brasileira de Ciencias.

[6]  J. Tuxhorn,et al.  Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia. , 2008, Urology.

[7]  S. Nie,et al.  Therapeutic Nanoparticles for Drug Delivery in Cancer , 2008, Clinical Cancer Research.

[8]  F. Hollande,et al.  Pygeum africanum extract inhibits proliferation of human cultured prostatic fibroblasts and myofibroblasts , 2006, BJU international.

[9]  K. McVary.  BPH: epidemiology and comorbidities. , 2006, The American journal of managed care.

[10]  J. Neuhaus,et al.  Saw palmetto for benign prostatic hyperplasia. , 2006, The New England journal of medicine.

[11]  M. Benahmed,et al.  Activation of caspases-3, -6, and -9 during finasteride treatment of benign prostatic hyperplasia. , 2006, The Journal of clinical endocrinology and metabolism.

[12]  A. Chugh,et al.  Benign prostatic hyperplasia: an insight into current investigational medical therapies , 2005, Expert opinion on investigational drugs.

[13]  A. Farré,et al.  Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia. , 2005, The Journal of urology.

[14]  J. Fitzpatrick,et al.  The role of a lipido‐sterolic extract of Serenoa repens in the management of lower urinary tract symptoms associated with benign prostatic hyperplasia , 2004, BJU international.

[15]  C. Roberts,et al.  Saw palmetto extract suppresses insulin-like growth factor-I signaling and induces stress-activated protein kinase/c-Jun N-terminal kinase phosphorylation in human prostate epithelial cells. , 2004, Endocrinology.

[16]  P. Boyle,et al.  Updated meta‐analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia , 2004, BJU international.

[17]  W. Costa,et al.  Stromal and acinar components of the transition zone in normal and hyperplastic human prostate , 2002, BJU international.

[18]  F. Lowe,et al.  Phytotherapy in the treatment of benign prostatic hyperplasia , 2002, Current opinion in urology.

[19]  B. P. da Silva,et al.  An anti-inflammatory and immunomodulatory polysaccharide from Orbignya phalerata. , 2001, Fitoterapia.

[20]  W. H. Goldmann,et al.  SAW PALMETTO BERRY EXTRACT INHIBITS CELL GROWTH AND COX‐2 EXPRESSION IN PROSTATIC CANCER CELLS , 2001, Cell biology international.

[21]  E. Koch.  Extracts from Fruits of Saw Palmetto (Sabal serrulata) and Roots of Stinging Nettle (Urtica dioica): Viable Alternatives in the Medical Treatment of Benign Prostatic Hyperplasia and Associated Lower Urinary Tracts Symptoms , 2001, Planta medica.

[22]  F. Habib,et al.  The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon) on the prostate. , 2000, The Journal of urology.

[23]  G. Clifford,et al.  Medical Therapy for Benign Prostatic Hyperplasia: A Review of the Literature , 2000, European Urology.

[24]  A. Partin,et al.  Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. , 2000, The Journal of urology.

[25]  G. Gerber.  Saw palmetto for the treatment of men with lower urinary tract symptoms. , 2000, The Journal of urology.

[26]  B. Huppertz,et al.  The apoptosis cascade — morphological and immunohistochemical methods for its visualization , 1999, Anatomy and Embryology.

[27]  T. Wilt,et al.  Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. , 1998, JAMA.

[28]  M. Nisolle,et al.  Vascular endothelial growth factor (VEGF) in endometriosis. , 1998, Human reproduction.

[29]  M. Barry,et al.  A 73-year-old man with symptomatic benign prostatic hyperplasia. , 1997, JAMA.

[30]  J. Nelson,et al.  Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  H. Ahn,et al.  Stromal cells of the human prostate: Initial isolation and characterization , 1996, The Prostate.

[32]  H. Heinzen,et al.  Triterpene methyl ethers from palmae epicuticular waxes , 1995 .

[33]  J. Oesterling,et al.  Benign prostatic hyperplasia. Medical and minimally invasive treatment options. , 1995, The New England journal of medicine.

[34]  S. Ben‐Sasson,et al.  Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation , 1992, The Journal of cell biology.

[35]  J. McNeal,et al.  Pathology of benign prostatic hyperplasia. Insight into etiology. , 1990, The Urologic clinics of North America.

[36]  P. Walsh,et al.  The development of human benign prostatic hyperplasia with age. , 1984, The Journal of urology.

[37]  D. Lorke.  A new approach to practical acute toxicity testing , 1983, Archives of Toxicology.

[38]  L. Angervall,et al.  ORAL TOXICITY OF POLYVINYL PYRROLIDONE PRODUCTS OF LOW AVERAGE MOLECULAR WEIGHT , 1961 .

[39]  P. Bénard,et al.  Distribution study of radioactivity in rats after oral administration of the lipido/sterolic extract ofSerenoa repens (Permixon®) supplemented with [1-14C]-lauric acid, [1-14C]-oleic acid or [4-14C]-β-sitosterol , 2010, European Journal of Drug Metabolism and Pharmacokinetics.

[40]  S. Cramer,et al.  A system for studying epithelial-stromal interactions reveals distinct inductive abilities of stromal cells from benign prostatic hyperplasia and prostate cancer. , 2005, Endocrinology.

[41]  G. Gerber,et al.  Saw palmetto and benign prostatic hyperplasia. , 2004, The American journal of Chinese medicine.

[42]  J. Fracchia,et al.  The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. , 2003, The Journal of urology.

[43]  C. Rhodes,et al.  Controlled-Release Drug Delivery Systems for Prolonged Gastric Residence: An Overview , 1996 .

[44]  P. Millett,et al.  Lactate dehydrogenase activity as a rapid and sensitive test for the quantification of cell numbers in vitro. , 1994, Clinical materials.

[45]  M. Maia,et al.  Anti‐inflammatory activity of Orbignia phalerata in rats , 1989 .